AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00258739
Drug: Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
RxNorm normalized name: Docetaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
Trial: NCT02797522
Drug: ARC-521 Injection
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02797522
Drug: antihistamine
RxNorm normalized name: Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
Trial: NCT02797522
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants take entecavir OR tenofovir daily throughout the study.
Trial: NCT02797522
Drug: tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants take entecavir OR tenofovir daily throughout the study.
Trial: NCT04398329
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine HCl, 50 mg
Trial: NCT02710331
Drug: Active Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg capsule of Dronabinol will be administered orally.
Trial: NCT03142854
Drug: Polyethylene Glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
Trial: NCT03142854
Drug: Polyethylene Glycol (PEG)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
Trial: NCT00551330
Drug: Vicriviroc
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of vicriviroc 30 mg once daily
Trial: NCT02330094
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Trial: NCT03487198
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brexpiprazole 2-3mg/day
Trial: NCT00999505
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine 200mg twice a day over 12 weeks
Trial: NCT03575637
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
Trial: NCT04645524
Drug: AD182
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule administered before bed
Trial: NCT04645524
Drug: AD504
RxNorm normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral capsule administered before bed
Trial: NCT00363896
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Trial: NCT00275522
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00703339
Drug: Treprostinil sodium for inhalation
RxNorm normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~* Cohort 1: dosed at 3 breaths (18 mcg)~* Cohort 2: dosed at 6 breaths (36 mcg)~* Cohort 3: dosed at 9 breaths (54 mcg)~* Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events.
Trial: NCT01052610
Drug: sublingual house dust mites allergen extract
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staloral 300 IR, Stallergenes, France
Trial: NCT02096042
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle.
Trial: NCT01907867
Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
RxNorm normalized name: eslicarbazepine
DrugBank: Finafloxacin (DB09047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00569114
Drug: TG01
RxNorm normalized name: TG01 vaccine
DrugBank: TG01 vaccine (DB17123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
Trial: NCT01886287
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide LAR as outlined in Treatment Arm.
Trial: NCT02096042
Drug: 5-Azacytidine
RxNorm normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
Trial: NCT00828906
Drug: DuoTrav
RxNorm normalized name: TRAVOPROST COMPONENT OF DUOTRAV
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: DuoTrav Eye Drops
Trial: NCT01168063
Drug: Molecular detection of antibiotic resistance
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
Trial: NCT02028325
Drug: Fluorescein Sodium
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
Trial: NCT01078961
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on days 1, 8 and 15 of each 28 day cycle
Trial: NCT01078961
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg taken orally twice a day
Trial: NCT01167452
Drug: Sulfamethoxazole/trimethoprim
RxNorm normalized name: SULFAMETHOXAZOLE/TRIMETHOPRIM
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
Trial: NCT00081575
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003877
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003877
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003877
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00532207
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous 20 micrograms
Trial: NCT00305838
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02771379
Drug: Idebenone
RxNorm normalized name: Idebenone
DrugBank: Idebenone (DB09081)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Trial: NCT01261000
Drug: Pegvisomant
RxNorm normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegvisomant used as indicated
Trial: NCT03019640
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03019640
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03019640
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03019640
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03019640
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03680352
Drug: cefepime/AAI101
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of cefepime and AAI101
Trial: NCT04481685
Drug: ATI-450
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.
Trial: NCT03406715
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
Trial: NCT01120873
Drug: Metamin 3D
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
Trial: NCT03406715
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
Trial: NCT04419233
Drug: Nusinersen Sodium Injection
RxNorm normalized name: nusinersen Injection
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as specified in the treatment arm.
Trial: NCT00806481
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
Trial: NCT01428427
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
Trial: NCT03769805
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
Trial: NCT00158522
Drug: pegylated interferon alpha2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02116569
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
Trial: NCT03678090
Drug: tPA standard dosage
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue plasminogen activator 25mg dosage
Trial: NCT03678090
Drug: tPA low dosage
RxNorm normalized name: low-density polyethylene
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue plasminogen activator 2.5mg
Trial: NCT01217788
Drug: PH94B intranasal spray
RxNorm normalized name: influenza A virus (H1N1) antigen
DrugBank: PH94B (DB04968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
Trial: NCT00504777
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg iv on days 1 and 15
Trial: NCT03133832
Drug: Companion Tablet
RxNorm normalized name: Companion Tablet
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chinese-made drug for schistosomiasis treatment
Trial: NCT03274973
Drug: Zomacton
RxNorm normalized name: Zomacton
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01154140
Drug: treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crizotinib 250mg orally continuous twice daily dosing
Trial: NCT01154140
Drug: treatment
RxNorm normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
Trial: NCT00416195
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04154852
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01417104
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/300mg
Trial: NCT02718261
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03766776
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
Trial: NCT01564277
Drug: rasburicase
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01564277
Drug: allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02754362
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
Trial: NCT02754362
Drug: Poly-ICLC as immune adjuvant
RxNorm normalized name: poly ICLC
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
Trial: NCT02754362
Drug: Keyhole limpet hemocyanin (KLH)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
DrugBank: Keyhole limpet hemocyanin (DB05299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
Trial: NCT01851551
Drug: Vincristine Sulfate Liposome Injection plus rituximab
RxNorm normalized name: vincristine sulfate liposome Injection
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01637077
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04030429
Drug: Crizotinib 250 MG
RxNorm normalized name: crizotinib 250 MG
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bid orally
Trial: NCT00246090
Drug: E7389
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
Trial: NCT00211380
Drug: aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
Trial: NCT04009460
Drug: ES101
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
Trial: NCT00909831
Drug: hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00909831
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04283890
Drug: Ipilimumab and nivolumab
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Trial: NCT04283890
Drug: Melphalan chemosaturation via percutaneous hepatic perfusion
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
Trial: NCT01224834
Drug: Sublingual tablet of ragweed pollen allergen extract
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered once a day over 10 days
Trial: NCT01589159
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 30mg/m2, once daily on days 1-7.
Trial: NCT00500344
Drug: Lucentis (ranibizumab)
RxNorm normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection
Trial: NCT04527484
Drug: SHR-1314
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: each group subjects will be given different formulations of SHR-1314
Trial: NCT01594970
Drug: Bimatoprost 0.01%
RxNorm normalized name: BIMATOPROST 0.01% OPH SOLN
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop in the affected eye(s), administered in the evening for 12 weeks.
Trial: NCT00953615
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Titrate to 400 mg daily for 6 months